[Correspondence] Fasting conditions in clinical oncology trials and drug labelling – Authors' reply

The main concern addressed in our Comment is that the interpretation of modified fasted intake of an oral oncolytic drug with a narrow therapeutic index can largely affect the exposure to the drug and thereby also treatment outcome, which is currently majorly ignored.

http://ift.tt/2eMXgUL